Bolsa ES - Gráfico Interactivo de Análisis Técnico de Bristol-Myers Squ [BMY]

Busque más análisis técnicos aquí en nuestro foro: Análisis Técnicos

Nota: Los datos después de 2012-05-16 son temporales y pueden tener un valor de Apertura incorrecto hasta nueva actualización...
Cambiar para Gráfico Estático de Bristol-Myers Squ

Bristol-Myers Squ - [Ticker: BMY]
Última Transacción	32,790	Hora de Cotización	2012-05-18 - 14:59
Variación	+0,040 (+0,120%)	Rango 52 Semanas	[25,690 - 35,440]
Máximo	32,990	Mínimo	32,780
Volumen	2.140.977	Volumen Medio (3m)	9.793.450
Demanda / Oferta	N/A	Yield	4,06
Cierre Anterior	32,750	PER	14,81%
Apertura	32,830	EPS	2,23
Fecha Ex-Dividendo	2012-05-18	Fecha Dividendo	2012-05-18
Capitalización Bursátil	56	Objetivo Estimado 1 Año	34,120
Nota: Los datos pueden tener un retraso de algunos minutos.

Noticias de Bristol-Myers Squ [BMY]: (ordenadas por relevancia)

Analysts' Actions: AZO, BMY, LLY, MS
TheStreet.com
Bristol-Myers(BMY) was initiated with an Outperform rating at BMO Capital. $39 price target. Company's growth potential is underestimated by the market, BMO Capital said. Cavium(CAVM) was downgraded at UBS to Neutral from Buy. $26 price target.

y más »

Lilly, Jaguar Land Rover, Viacom: Intellectual Property
Bloomberg
(LLY) and AstraZeneca Plc (AZN) won't have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)'s Plavix after the drug lost US patent protection yesterday. Lilly's Effient and AstraZeneca's Brilinta ...
Daily Trade Flow Review for Bristol-Myers Squibb Company (BMY)AVAFIN
Healthcare Business Recap: Dendreon's New Hell, Bristol-Myers Squibb Hates ...Wall St. Cheat Sheet
Another one bites the dust: Plavix falls off patent todayFiercePharma
Investorplace.com
los 19 artículos informativos »

Dividend.com (blog)

Bristol Myers Squibb Started as ?Outperform? at BMO Capital (BMY)
Dividend.com (blog)
By Dividend.com Staff Pharmaceuticals giant Bristol Myers Squibb Co. (BMY) on Friday caught some bullish commentary from analysts at BMO Capital. The firm initiated coverage on BMY with an ?Outperform? rating and $39 price target, which suggests a 19% ...
Updated: Bristol-Myers starts Orencia manufacturing at new plantThe Mumbai Times

los 3 artículos informativos »

Moneycontrol.com

Bristol-Myers anticipates significant decline in US clopidogrel sales as ...
The Pharma Letter
... recently published an article based on its proprietary Pipeline Patent Intelligence that analyses opportunities in launching generic versions of French drug major Sanofi (Euronext: SAN) and US partner Bristol Myers Squibb's (NYSE: BMY) blockbuster ...
Bristol-Myers, Sanofi blockbuster drug Plavix topples over patent cliffMedCity News
Generic floodgates open for Plavix in USFiercePharma
FDA Approves Generic Versions Of Blood-Thinning Drug PlavixNASDAQ
RTT News
los 254 artículos informativos »

Asian Scientist Magazine

Manufacturing Facility Cleared at BMY
Zacks.com
Bristol-Myers Squibb Company (BMY - Analyst Report) received some encouraging news when the US Food and Drug Administration (FDA) cleared a biologics manufacturing facility of the company for producing its rheumatoid arthritis (RA) drug, Orencia.
Bristol-Myers Squibb receives FDA approval for Devens facility to produce ORENCIANews-Medical.net
Bristol-Myers Squibb and Tsinghua University Enter Strategic PartnershipMarketWatch (press release)
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility ...EON: Enhanced Online News (press release)
Sacramento Bee
los 98 artículos informativos »

U.S. News & World Report

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 ...
MarketWatch (press release)
Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on its approved and investigational oncology compounds will be featured in ten oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in ...
ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)TheStreet.com
Highlights of presentations planned for ASCO meetingThe Pharma Letter

los 103 artículos informativos »

Updated: Stocks Reaching Trendline Support (Bullish) on May-17
The Mumbai Times
Bristol-Myers Squibb Company (NYSE:BMY) is currently trading at $33.02. BMY is trading -0.50% below its 50 day moving average and 4.56% above its 200 day moving average. BMY is -5.66% below its 52-week high and 32.44% above its 52-week low.

y más »

Bloomberg

Bristol-Myers Meets Estimates as Pipeline Remains Focus
Bloomberg
Bristol-Myers Squibb Co. (BMY), losing its top-seller Plavix to generic competition next month, matched analyst estimates on sales of newer drugs as investors remain focused on the company's pipeline. Net income rose 12 percent to $1.1 billion, ...
Bristol-Myers 1Q Net Rises 12% On High Cancer Drug SalesWall Street Journal
Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating ...MarketWatch (press release)
Bristol-Myers Profit Climbs, Backs ForecastNASDAQ
Fox Business
los 101 artículos informativos »

Amylin Said to Attract Interest From Pfizer, AstraZeneca
BusinessWeek
(4502), Roche Holding AG (ROG) and Bristol-Myers Squibb Co. (BMY) (BMY) also signed agreements to get access to confidential financial and product information for Amylin, said the people, who declined to be identified as talks are private.

y más »

Breaking News: The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs ...
The Mumbai Times
Stocks recently featured in the blog include Gilead Sciences (GILD - Analyst Report), Abbott Labs (ABT - Analyst Report), Alliance Data Systems Corporation (ADS - Snapshot Report), Blue Nile (NILE - Snapshot Report) and Bristol-Myers Squibb (BMY ...

New Stock Coverage: Sun Shines on Hawaiian Holdings
Minyanville.com
Drug stocks: Bristol-Myers (BMY) is initiated with an Outperform at BMO Capital, which assigns more modest Market Performs on Eli Lilly and Merck (MRK). Exactech (EXAC): Shares are begun with a Buy at The Benchmark Company, whose target price is $21.

y más »

Bristol-Myers Squibb To Present At Bank Of America Merrill Lynch Health Care ...
TheStreet.com (press release)
By Business Wire 05/10/12 - 11:00 AM EDT Bristol-Myers Squibb Company (NYSE: BMY) will present at Bank of America Merrill Lynch Health Care Conference on Thursday, May 17, 2012 in Las Vegas. Doug Manion, senior vice president, Development, Neuroscience ...

y más »

3 Meaningfully Undervalued Healthcare Stocks
Seeking Alpha
As attractive as Bristol Myers (BMY) and Johnson & Johnson (JNJ) are from a risk-mitigation standpoint, Emergent Health Corp (EMGE.PK) is likely to generate higher returns. Its winning combination of attractive lines in regenerative medicine, ...

Goodbye Plavix, hello, competition
Medical Marketing and Media
The Bristol-Myers Squibb brand, which has far and away held the number-one spot in anti-platelet sales in the US from 2007 through 2011, according to IMS Health, came up for generic competition Thursday. Plavix raked in $27.2 billion in US sales alone ...

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data ...
Zacks.com
Stocks recently featured in the blog include Gilead Sciences (GILD - Analyst Report), Abbott Labs (ABT - Analyst Report), Alliance Data Systems Corporation (ADS - Snapshot Report), Blue Nile (NILE - Snapshot Report) and Bristol-Myers Squibb (BMY ...

y más »

Para más noticias de Bristol-Myers Squ hacer clic aquí:
Noticias de Bristol-Myers Squ